HI
APLS

Handelsinvest Investeringsforvaltning’s Apellis Pharmaceuticals APLS Stock Holding History

Handelsinvest Investeringsforvaltning’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$159K Sell
2,697
-1,400
-34% -$89.2K 0.08% 296
2023
Q4 		$245K Buy
+4,097
New +$208K 0.1% 296

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Handelsinvest Investeringsforvaltning's APLS Position: Q1 2024 in Review

Handelsinvest Investeringsforvaltning reduced its Apellis Pharmaceuticals (APLS) stake by 34% in Q1 2024, selling an estimated $89.2K and leaving 2,697 shares worth $159K. The position accounts for 0.08% of the portfolio, ranked #296.

Handelsinvest Investeringsforvaltning first reported a position in APLS in Q4 2023 and has held it in 2 quarters since. The position peaked at $245K in Q4 2023. 302 funds tracked by Wall St. Rank hold APLS as of Q1 2024.

  • Handelsinvest Investeringsforvaltning held 2,697 shares of Apellis Pharmaceuticals worth $159K as of Q1 2024.
  • Handelsinvest Investeringsforvaltning sold 1,400 Apellis Pharmaceuticals shares in Q1 2024, an estimated $89.2K.
  • Apellis Pharmaceuticals made up 0.08% of Handelsinvest Investeringsforvaltning's portfolio in Q1 2024, its #296 holding.
  • Handelsinvest Investeringsforvaltning first reported a position in Apellis Pharmaceuticals in Q4 2023 and has held it in 2 quarters since.
  • Handelsinvest Investeringsforvaltning's Apellis Pharmaceuticals position peaked at $245K in Q4 2023.
  • 302 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2024.

Based on Handelsinvest Investeringsforvaltning's 13F filing for Q1 2024, filed 19 Apr 2024.